T-Cell Depleted CD34+ PBSC Transplants After Chemotherapy Conditioning as Treatment for Hematologic Malignancies and as a Platform for Cellular Immunotherapies
Richard O’Reilly, M.D. discusses current allogeneic transplant approaches, different conditioning regimens and pros/cons for different strategies.
Hematologists, oncologists, pathologists, radiation oncologists, physician assistants, nurses, nurse practitioners, palliative care staff, pharmacists and other allied health care team members interested in the treatment of patients with hematologic malignancies.
- Implement current allogeneic transplant approaches.
- Assess strategies with the different conditioning regimen.
- Compare the pros and cons of allogeneic transplant strategies.
The Continuing Medical Education Department gratefully acknowledges the following organizations for providing support of high quality unbiased continuing medical education at the Immunotherapy Symposium, at which the content for this online activity was recorded:
Jazz Pharmaceuticals, Inc.
Richard O’Reilly, M.D.
Claire L. Tow Chair in Pediatric Oncology Research
Memorial Sloan Kettering Cancer Center
New York, New York
Richard O’Reilly, M.D., has indicated that he is a consultant with Atara Biotherapeutics, and he will include off-label or unapproved product usage in his presentation or discussion.
This online course is a highlight from the Inaugural Miami Cancer Institute Immunotherapies Summit.
Guenther Koehne, M.D., Ph.D.
Deputy Director of Miami Cancer Institute
Chief of Blood & Marrow Transplant and Hematologic Oncology
Miami Cancer Institute
Robert Sackstein, M.D.
Interim Chair, Department of Translational Medicine
Dean and Senior Vice President for Health Affairs, and Professor
Florida International University
Guenther Koehne, M.D., Ph.D., has indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation or discussion.
Robert Sackstein, M.D., has indicated that he is a consultant with Biotechne/R&D Systems and Mesoblast LTD, and he has licenses with Warrior Therapeutics LLC, Mesoblast Ltd., and Biotechne/R&D Systems. He also has equity with Warrior Therapeutics, LLC. He will not include off-label or unapproved product usage in his presentation or discussion.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Pharmacy
This site is supported on the most recent stable releases of the following browsers:
This site is supported on the following mobile devices:
If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.